Apax Global Q1 hit by poor performance at Vyaire
reported lower net asset value and took a €24m writedown across its private equity and debt portfolios after a poor performance at Vyaire Medical.
Total NAV return fell 0.5% in the three months to March 31 as performance was impacted by "negative developments" at Vyaire although no details were supplied.
AGA's adjusted NAV was €1.25bn at the end of the quarter, compared to €1.29bn at the end of 2023.
"The contribution of earnings to Q1 private equity returns slowed driven by a small number of portfolio companies, including Vyaire," Apax said.
"Following materially deteriorating trading at Vyaire during Q1, AGA has taken a €24m writedown on its value across the private equity and debt portfolios, reducing AGA's Private Equity exposure to Vyaire to €5m and debt exposure to Vyaire's first lien loan to €12m."
Reporting by Frank Prenesti for Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.